Andra AP fonden increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 17.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 42,100 shares of the medical device company’s stock after purchasing an additional 6,300 shares during the period. Andra AP fonden’s holdings in DexCom were worth $5,410,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently modified their holdings of the stock. Bank Julius Baer & Co. Ltd Zurich raised its position in shares of DexCom by 141,272.2% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 47,321,524 shares of the medical device company’s stock worth $6,081,289,000 after purchasing an additional 47,288,051 shares during the last quarter. Geode Capital Management LLC raised its holdings in DexCom by 2.1% in the 1st quarter. Geode Capital Management LLC now owns 8,282,663 shares of the medical device company’s stock valued at $960,174,000 after acquiring an additional 170,796 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in DexCom by 1.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,033,924 shares of the medical device company’s stock valued at $456,802,000 after acquiring an additional 44,260 shares during the last quarter. Norges Bank acquired a new stake in DexCom in the 4th quarter valued at about $421,378,000. Finally, Federated Hermes Inc. raised its holdings in DexCom by 5.7% in the 1st quarter. Federated Hermes Inc. now owns 2,318,204 shares of the medical device company’s stock valued at $269,329,000 after acquiring an additional 125,725 shares during the last quarter. Institutional investors and hedge funds own 93.88% of the company’s stock.
Wall Street Analyst Weigh In
A number of research firms have commented on DXCM. UBS Group cut their price objective on shares of DexCom from $175.00 to $138.00 and set a “buy” rating for the company in a report on Wednesday, September 6th. Raymond James cut their price objective on shares of DexCom from $154.00 to $131.00 and set a “strong-buy” rating for the company in a report on Friday, September 15th. Piper Sandler increased their price objective on shares of DexCom from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Friday, July 28th. StockNews.com initiated coverage on shares of DexCom in a report on Thursday, October 5th. They issued a “hold” rating for the company. Finally, Robert W. Baird decreased their price target on shares of DexCom from $153.00 to $130.00 and set an “outperform” rating for the company in a research report on Monday, August 21st. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $130.93.
DexCom Stock Performance
Shares of DXCM opened at $101.38 on Wednesday. The company has a current ratio of 2.80, a quick ratio of 2.50 and a debt-to-equity ratio of 1.07. The stock has a market cap of $39.17 billion, a P/E ratio of 111.41, a PEG ratio of 1.99 and a beta of 1.13. The company has a 50-day moving average of $91.11 and a two-hundred day moving average of $110.06. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $139.55.
DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings data on Thursday, October 26th. The medical device company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.16. The business had revenue of $975.00 million during the quarter, compared to analyst estimates of $939.64 million. DexCom had a net margin of 11.08% and a return on equity of 25.05%. The company’s revenue was up 26.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.28 earnings per share. As a group, research analysts predict that DexCom, Inc. will post 1.41 EPS for the current fiscal year.
Insider Buying and Selling
In other DexCom news, CFO Jereme M. Sylvain sold 1,844 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $104.38, for a total transaction of $192,476.72. Following the completion of the sale, the chief financial officer now directly owns 72,867 shares in the company, valued at $7,605,857.46. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Jereme M. Sylvain sold 1,844 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $104.38, for a total value of $192,476.72. Following the completion of the transaction, the chief financial officer now directly owns 72,867 shares in the company, valued at $7,605,857.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven R. Altman sold 1,000 shares of the company’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $77.58, for a total transaction of $77,580.00. Following the completion of the transaction, the director now owns 60,700 shares of the company’s stock, valued at $4,709,106. The disclosure for this sale can be found here. Over the last quarter, insiders sold 7,752 shares of company stock valued at $749,037. Insiders own 0.41% of the company’s stock.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
- Five stocks we like better than DexCom
- What Are Dividend Champions? How to Invest in the Champions
- Analyst says Archer Aviation may double. Is it time to buy?
- Investing in the Best Airline Stocks
- Alibaba’s bottom is in: Analysts see a monster rally ahead
- How to Buy Cheap Stocks Step by Step
- TripAdvisor is on AI-powered recovery from record lows
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.